65,437 trials
Metastatic Cancer · Pain · Prostate Cancer
Primary: 8-week Freedom-From-Progression (FFP) — 2; 15 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12 — 0.18; 0.04; -0.24; -0.28 percent — p=0.3271
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 24 — 0.15; -0.49 Percent — p=<0.0001
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline to Week 24 — -0.56; -1.06 Percent — p=<0.0001
Coronary Artery Disease · Coronary Artery Bypass · Erythrocyte Transfusion
Primary: Mean Number of Packed Red Cells Units Transfused During Hospital Stay — 1.13; 1.91 packed red cells units — p=<0.05
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 6.05; 4.50 months
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 24 — 0.25; -0.44 Percent — p=<0.0001
Major Depressive Disorder
Primary: Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET) — -8.52; -8.98; -10.02 Units on a scale — p=0.452
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -11.1; -12.3; -6.9 mmHg
Amblyopia
Primary: Distribution of Visual Acuity in the Amblyopic Eye at 17 Weeks — 0; 0; 0; 0 participants
Multiple Myeloma
Primary: The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months — 17; 13 Participants
Non-Hodgkin's Lymphoma
Primary: Number of Participants With Progression Free Survival at 2 Years — 13 Participants
Hypertension
Primary: Number of Patients With Adverse Events — 16; 11; 51; 53 Participants
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.292; 0.029 Proportion of participants — p=< 0.0001